PRESS RELEASE
1st July 2021

ERS Genomics and Nippon Gene sign CRISPR/Cas9 license
agreement
License agreement to enhance Nippon Gene’s CRISPR/Cas9 research reagentsoffering
Dublin, Ireland and Tokyo, Japan, 1st July 2021: ERS Genomics Limited, which was formed to provide
broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle
Charpentier, and Nippon Gene Co., Ltd (Nippon Gene), a manufacturer of genetic engineering research
reagents and diagnostic reagents for humans, animals, and plants, today announced a non-exclusivelicense agreement granting Nippon Gene access to ERS Genomics’ CRISPR/Cas9 patent portfolio.
Nippon Gene is a biotechnology company manufacturing and providing research reagents, across Japan.
The portfolio of reagents for research includes enzymes, buffers and reagents for LAMP and PCR kits.
Nippon Gene also provides plant disease diagnostic kits, allergen detection kits, and antibiotics detection
kits in addition to pregnancy and ovulation tests. The license from ERS Genomics will allow Nippon Geneto develop, manufacture, and sell research reagents using CRISPR/Cas9 technology.
ERS Genomics holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr.
Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as aresearch platform.
Eric Rhodes, CEO of ERS Genomics, said: “Our portfolio of Japanese companies taking a license tothe CRISPR/Cas9 technology is growing rapidly, and we are very pleased to be working with Nippon
Gene. Supporting the company with this license agreement will allow them to continue providing crucialreagents to the life science research community.”
Shinji Kanayama, President of Nippon Gene, commented: “CRISPR/Cas9 technology has
revolutionized life science research, becoming an important technology applied across a variety of fields.
The license from ERS Genomics, granting us access to the foundational CRISPR/Cas9 patents, will
enable us to supply a wide range of research reagents in the field of gene editing. We will continue toexpand our genome-editing related reagents to support the advancement and development of cuttingedge life sciences.”
Financial details of the agreement are not disclosed.
ENDS

Eric Rhodes, CEO,ERS Genomics

For high resolution images please contact Zyme Communications
Media contact:
Katie Odgaard
Zyme Communications
Tel: +44(0)7787 502 947
Email: katie.odgaard@zymecommunications.com
Contact Nippon Gene:
https://www.nippongene.com/english/contact/contact.html
Contact ERS Genomics:
Summit Pharmaceuticals International Corporation(The exclusive agent for ERS Genomics in Japan)
Email: alliance@summitpharma.co.jp
To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com.
To view our privacy policy please click here.
About ERS Genomics www.ersgenomics.com
ERS Genomics is a biotechnology company based in Dublin, Ireland. The company was formed to provide broad
access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive
licenses are available for research and sale of products and services across multiple fields including: research tools,
kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel
drug candidates; GMP production of healthcare products; companion animal and livestock health; production ofindustrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please
visit www.ersgenomics.com.
About Nippon Gene Co., Ltd. https://www.nippongene.com/english/index.html
Nippon Gene is a biotechnology company founded in 1982 in Japan. Based on the basic policy of "supporting theadvancement and development of sound life sciences," the Company produces and supplies various research
reagents in Japan, including enzymes used in research and development in the life sciences field, as well as
reagents for nucleic acid extraction and gene amplification. In addition, Nippon Gene develops, manufactures, andsells in vitro diagnostics, as well as other tests and diagnostics for biotechnology applications including theenvironment, food, and animal and plant diseases. For additional information please visit
https://www.nippongene.com/english/index.html